Current opinion in biotechnology最新文献_第8页

Emerging strategies to enhance microbial natural product–based drug discovery 新兴战略加强微生物天然产物为基础的药物发现

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-10-10 DOI: 10.1016/j.copbio.2025.103369

Michael Madden , Conor Pulliam , Katherine Holandez-Lopez , Andrew Campbell , Jie Li

引用次数: 0

Programmable probiotics as next-generation living therapeutics: bridging synthetic biology and precision medicine 可编程益生菌作为下一代生命疗法：连接合成生物学和精准医学。

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-11-04 DOI: 10.1016/j.copbio.2025.103375

Na Li , Lijie Yin , Jia Wang , Jing Zhang , Yaojun Tong

{"title":"Programmable probiotics as next-generation living therapeutics: bridging synthetic biology and precision medicine","authors":"Na Li , Lijie Yin , Jia Wang , Jing Zhang , Yaojun Tong","doi":"10.1016/j.copbio.2025.103375","DOIUrl":"10.1016/j.copbio.2025.103375","url":null,"abstract":"<div><div>Engineered probiotics are rapidly redefining what’s possible for living therapeutics. Instead of acting passively, these microbes can now home to disease sites, sense local signals, and deliver precisely the therapeutic activities our patients need — directly <em>in situ</em> and for extended periods. With the help of modular genetic circuits, synthetic biology is transforming once-commensal bacteria into sophisticated, programmable medicines. In this review, we highlight how these designer microbes are tackling inflammatory bowel disease, metabolic conditions, and cancer, and we offer a critical look at the strategies underpinning their safety, efficacy, and clinical translation. We also discuss the translational bottlenecks, such as biocontainment, regulatory complexity, and microbiome variability, that must be overcome as these living medicines move from concept toward routine clinical use. Ultimately, programmable probiotics stand poised to reshape pharmaceutical biotechnology, sitting squarely at the intersection of microbiology, engineering, and precision medicine.</div></div>","PeriodicalId":10833,"journal":{"name":"Current opinion in biotechnology","volume":"96 ","pages":"Article 103375"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for engineering domesticated and undomesticated human microbes 驯化和未驯化人类微生物的工程策略。

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-10-04 DOI: 10.1016/j.copbio.2025.103368

Dake Liu, Meng-Lun Hsieh, Yousong Ding

引用次数: 0

Designed dietary fibers: engineering carbohydrate structure for precision modulation of the human gut microbiome 设计膳食纤维：工程碳水化合物结构，精确调节人类肠道微生物群

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-10-23 DOI: 10.1016/j.copbio.2025.103371

Marcelo Iñaki Guerrero Montalván , Mariana Guzmán Sánchez , Victoria Gutierrez , Yunus E Tunçil , Stephen R Lindemann

引用次数: 0

From marsh to market: taming Vibrio natriegens for sustainable bioproduction 从沼泽到市场：培育可持续生物生产所需的营养弧菌

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-09-12 DOI: 10.1016/j.copbio.2025.103353

Simona Della Valle , Anna Faber , Roland J Politan , Suman Lama , Georg Fritz

引用次数: 0

Molecules to medicine: advances in metabolomics for natural product drug discovery 分子到医学：天然产物药物发现的代谢组学进展

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-10-31 DOI: 10.1016/j.copbio.2025.103373

Victoria Deleray , Pieter C Dorrestein , Nicole E Avalon

{"title":"Molecules to medicine: advances in metabolomics for natural product drug discovery","authors":"Victoria Deleray , Pieter C Dorrestein , Nicole E Avalon","doi":"10.1016/j.copbio.2025.103373","DOIUrl":"10.1016/j.copbio.2025.103373","url":null,"abstract":"<div><div>Recent advances in metabolomics are accelerating natural product (NP) drug discovery. NPs possess diverse biological relevance and comprise a significant portion of our modern pharmacopeia. We highlight studies from the past two years with innovative discovery techniques, ranging from small sample analyses to large-scale data-driven approaches. We focus on nuclear magnetic resonance- and mass spectrometry-based metabolomics for their broad use and greatest advancements in the field. We highlight strategies that utilize computational tools to enable prioritization of samples based on structural novelty, cross-referencing structural data with bioactivity, and the development of innovative annotation techniques that surpass common library matching methods. We also look at the trajectory of metabolomic discovery of NPs over the last decade to inform how these platforms may further evolve. The goal is to enhance the likelihood and improve the efficiency of discovering NPs with pharmaceutical potential, while strategically harnessing data in order to reduce rediscovery and methodological redundancy.</div></div>","PeriodicalId":10833,"journal":{"name":"Current opinion in biotechnology","volume":"96 ","pages":"Article 103373"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145412718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resolving misconceptions and constraints in growth-coupled bioproduction 解决生长耦合生物生产中的误解和限制

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-11-21 DOI: 10.1016/j.copbio.2025.103388

Lena M Hümmler , Stefan Hristov , Lucas Hille , Elad Noor , Steffen N Lindner

{"title":"Resolving misconceptions and constraints in growth-coupled bioproduction","authors":"Lena M Hümmler , Stefan Hristov , Lucas Hille , Elad Noor , Steffen N Lindner","doi":"10.1016/j.copbio.2025.103388","DOIUrl":"10.1016/j.copbio.2025.103388","url":null,"abstract":"<div><div>Growth-coupled bioproduction (GCBP) is a metabolic engineering approach that introduces an obligatory dependency between metabolic activity and production, ensuring a high minimal yield and genetic stability. Here, product yield is primarily limited by pathway constraints, which can be overcome by further metabolic engineering. However, misconceptions persist in understanding GCBP among metabolic and process engineers. Contrary to misperceptions, yield is not stoichiometrically constrained by the growth-restoring enzymatic step, cell division is nonessential for production, and GCBP is compatible with multistage fermentation processes. Finally, GCBP addresses reduced production arising from genetic drift caused by population heterogeneity. Still, challenges remain: the lack of metabolic engineering tools for nonmodel organisms, limited <em>in silico</em> design capabilities, and the existence of uncharacterized metabolism. Nevertheless, by setting a high minimal stoichiometric yield, GCBP facilitates continuous bioproduction. Overall, integrating GCBP with metabolic engineering and improved computational design has the potential to reshape industrial biotechnology toward robust and efficient bioproduction.</div></div>","PeriodicalId":10833,"journal":{"name":"Current opinion in biotechnology","volume":"96 ","pages":"Article 103388"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Production of chemicals by metabolically engineered Escherichia coli 通过代谢工程改造的大肠杆菌生产化学物质。

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-10-06 DOI: 10.1016/j.copbio.2025.103367

Gyudong Jang , Min-Jung Kim , Sang Yup Lee

{"title":"Production of chemicals by metabolically engineered Escherichia coli","authors":"Gyudong Jang , Min-Jung Kim , Sang Yup Lee","doi":"10.1016/j.copbio.2025.103367","DOIUrl":"10.1016/j.copbio.2025.103367","url":null,"abstract":"<div><div><em>Escherichia coli</em> is increasingly employed for chemical production, with its industrial competitiveness now depending on both the expansion of its molecular repertoire through first-in-class pathways and achieving best-in-class titer, rate, and yield (TRY). Recent milestones include the first demonstration of producing aromatic homopolyester and poly(ester amide)s from glucose using engineered <em>E. coli</em>. To optimally maximize TRY, systems metabolic engineering leverages diverse tools such as genome-scale CRISPRi/sRNA libraries, dynamic biosensors, and redox-balancing modules to optimally channel cellular resources toward product formation. In parallel, <em>in silico</em> tools support retrobiosynthetic pathway design, flux optimization, and enzyme engineering. By integrating first-in-class pathway construction with best-in-class TRY optimization, <em>E. coli</em> is poised to drive the next generation of sustainable, large-scale biomanufacturing. Overall, this review outlines representative achievements, strategic approaches, and emerging prospects, highlighting how recent advancements are positioning <em>E. coli</em> as a versatile and competitive chassis for sustainable production of value-added chemicals and materials.</div></div>","PeriodicalId":10833,"journal":{"name":"Current opinion in biotechnology","volume":"96 ","pages":"Article 103367"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineering metabolism of Saccharomyces cerevisiae for production of chemicals 用于化工生产的酿酒酵母菌工程代谢。

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-11-18 DOI: 10.1016/j.copbio.2025.103387

Yi Yu , Xiaoying Fu , Jinmiao Hu , Jens Nielsen , Shuobo Shi

{"title":"Engineering metabolism of Saccharomyces cerevisiae for production of chemicals","authors":"Yi Yu , Xiaoying Fu , Jinmiao Hu , Jens Nielsen , Shuobo Shi","doi":"10.1016/j.copbio.2025.103387","DOIUrl":"10.1016/j.copbio.2025.103387","url":null,"abstract":"<div><div>The sustainable production of chemicals from renewable, nonedible biomass has become crucial to address environmental challenges like climate change and resource depletion caused by fossil resource dependence. <em>Saccharomyces cerevisiae</em> has emerged as a versatile microbial chassis for industrial bioproduction of chemicals, with engineered breakthroughs in central carbon metabolism, lipid metabolism, and terpenoid metabolism. This review examines three transformative paradigms: (1) optimizing metabolic flux and redirecting yeast pathways for chemical biosynthesis (e.g. farnesene), (2) enhancing yeast robustness to improve biomass and biochemical production under fermentation stresses (e.g. succinic acid), and (3) expanding feedstock flexibility through engineered substrate assimilation (e.g. ethanol). These examples pave the way for producing sustainable chemicals. We also discuss future challenges and propose AI (Artificial Intelligence)-driven design tools, CRISPR-based genome editing, and integrated biological-chemical hybrid processes as next-generation solutions to advance a yeast-mediated circular bioeconomy.</div></div>","PeriodicalId":10833,"journal":{"name":"Current opinion in biotechnology","volume":"96 ","pages":"Article 103387"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Building trust in automated experimentation: uncertainty quantification in the era of high-throughput biolabs 在自动化实验中建立信任：高通量生物实验室时代的不确定度量化。

IF 7 2区工程技术

Current opinion in biotechnology Pub Date : 2025-12-01 Epub Date: 2025-11-13 DOI: 10.1016/j.copbio.2025.103382

Wolfgang Wiechert , Laura M Helleckes , Katharina Nöh

引用次数: 0